Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

French MBE firm Riber has signed a three-year collaboration with the Novo Nordisk Foundation Quantum Computing Programme ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Tarang Amin, head of e.l.f. Beauty, bought up shares of packaged-foods firm J.M. Smucker, which he serves as a director.

RIBER completes phase I of ROSIE with a partnership agreement signed with NQCP, a leading research center in Denmark Bezons (France), June 17, 2025 – 6:00pm (CET) – RIBER, the global leader in ...

Our annual list features 25 leaders whose deft guidance has put their companies in a stronger competitive position.

(Reuters) -European shares edged higher on Monday, rebounding from last week's losses, as investors shook off jitters ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...